Fgf21 nash

Fibroblast growth factor 21 (FGF21) and its analogs have emerged as a potential new therapeutic strategy for the treatment of NASH. In fact, FGF21 deficiency favors the development of steatosis, inflammation, hepatocyte damage, and fibrosis in the liver, whereas administration of FGF21 analogs ameliorates NASH by attenuating these processes.

Background and purpose: Non-alcoholic steatohepatitis (NASH) is the most severe form of non-alcoholic fatty liver disease and is a serious public health problem around the world. There are currently no approved treatments for NASH. FGF21 has recently emerged as a promising drug candidate for metabolic diseases.

Fibroblast Growth Factor 21 (FGF21) is secreted by hepatocytes. FGF21 stimulates glucose uptake in differentiated adipocytes. The FGF21 Wikipedia page gives a more fanciful review of the literature concerning FGF21 and behaviors such as the “sweet tooth.” The protective role of FGF21 are also discussed..

Hepatic FGF21 expression is regulated by the peroxisome proliferator-activated receptor (PPAR)-α pathway and the exchange protein directly activated by cyclic adenosine monophosphate (EPAC)/protein kinase A (PKA) pathway. The PPARα pathway is activated by FFAs and/or protein insufficiency, which increases FGF21 gene expression [ 23 ].

FGF19 and FGF21 are atypical members of the FGF superfamily. As opposed to classical FGFs, these proteins have only weak or no heparin-binding affinity, allowing them to enter into general circulation and function in an endocrine manner to regulate various aspects of lipid and carbohydrate metabolism [,,,, ].

In a scientific publication at the recent AASLD liver meeting in San Franciso, Genfit published data confirming that the hormone FGF21 clearly distinguished between responders and non responders of untreated Nash patients to Elafibranor in the Golden phase IIB study.

FGF19 and FGF21 are atypical members of the FGF superfamily. As opposed to classical FGFs, these proteins have only weak or no heparin-binding affinity, allowing them to enter into general circulation and function in an endocrine manner to regulate various aspects of lipid and carbohydrate metabolism [,,,, ].

Preclinical and clinical data suggest that fibroblast growth factor 21 (FGF21) is anti-fibrotic, improves metabolic status and has potential to treat non-alcoholic steatohepatitis (NASH). We…

Fibroblast growth factor 21 (FGF21) has become a promising therapeutic target for metabolic diseases such as type 2 diabetes (T2D), obesity and non-alcoholic steatohepatitis. However, the clinical application of natural FGF21 molecule is limited because of its instability in vitro and short half-life in vivo.

Ingelheim, Germany and Seoul, Korea – 1 July 2019 – Boehringer Ingelheim and Yuhan Corporation today announced a collaboration and license agreement for the development of a first-in-class dual agonist for the treatment of NASH and related liver diseases that combines GLP-1 and FGF21 activity in one molecule.